OR10A2

Across TCGA pan-cancer cohorts, OR10A2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR10A2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR10A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR10A2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, LUAD, and COAD are the cancer types where OR10A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.093	0.783	<.001	30	view →
LUAD	OS	Median	III,IV	0.158	0.663	.008	12	view →
COAD	OS	Median	All	0.305	0.802	.009	3	view →
SKCM	DFS	Median	II,III,IV	0.872	0.560	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR10A2–LIHC (OS)

Open the LIHC breakdown →